[go: up one dir, main page]

EP4259138A4 - METHODS OF TREATING HEART DISEASE WITH MODIFIED FORMS OF TRIMETAZIDINE - Google Patents

METHODS OF TREATING HEART DISEASE WITH MODIFIED FORMS OF TRIMETAZIDINE Download PDF

Info

Publication number
EP4259138A4
EP4259138A4 EP21904143.1A EP21904143A EP4259138A4 EP 4259138 A4 EP4259138 A4 EP 4259138A4 EP 21904143 A EP21904143 A EP 21904143A EP 4259138 A4 EP4259138 A4 EP 4259138A4
Authority
EP
European Patent Office
Prior art keywords
trimetazidine
methods
heart disease
modified forms
treating heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21904143.1A
Other languages
German (de)
French (fr)
Other versions
EP4259138A1 (en
Inventor
Jaikrishna Patel
Paul Chamberlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imbria Pharmaceuticals Inc
Original Assignee
Imbria Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imbria Pharmaceuticals Inc filed Critical Imbria Pharmaceuticals Inc
Publication of EP4259138A1 publication Critical patent/EP4259138A1/en
Publication of EP4259138A4 publication Critical patent/EP4259138A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP21904143.1A 2020-12-10 2021-12-02 METHODS OF TREATING HEART DISEASE WITH MODIFIED FORMS OF TRIMETAZIDINE Pending EP4259138A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063123715P 2020-12-10 2020-12-10
US202063123721P 2020-12-10 2020-12-10
US202063123711P 2020-12-10 2020-12-10
US202063123728P 2020-12-10 2020-12-10
PCT/US2021/061583 WO2022125370A1 (en) 2020-12-10 2021-12-02 Methods of treating heart conditions using modified forms of trimetazidine

Publications (2)

Publication Number Publication Date
EP4259138A1 EP4259138A1 (en) 2023-10-18
EP4259138A4 true EP4259138A4 (en) 2024-11-06

Family

ID=82932763

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21904143.1A Pending EP4259138A4 (en) 2020-12-10 2021-12-02 METHODS OF TREATING HEART DISEASE WITH MODIFIED FORMS OF TRIMETAZIDINE

Country Status (2)

Country Link
EP (1) EP4259138A4 (en)
WO (1) WO2022125370A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243120A1 (en) * 2019-05-31 2020-12-03 Imbria Pharmaceuticals, Inc. Methods of treating fibrosis using compounds that promote glucose oxidation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530337B (en) * 2014-12-22 2021-07-09 贝克心脏与糖尿病研究所 treatment method
WO2017147532A1 (en) * 2016-02-26 2017-08-31 The Regents Of The University Of California Alpha-1-adrenergic receptor agonist therapy
US12318382B2 (en) * 2018-10-17 2025-06-03 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
EP3976103A4 (en) * 2019-05-31 2023-06-28 Imbria Pharmaceuticals, Inc. Methods of altering cardiac remodeling using compounds that promote glucose oxidation
US20220226313A1 (en) * 2019-06-03 2022-07-21 Imbria Pharmaceuticals, Inc. Combination therapies that include an agent that promotes glucose oxidation and an inhibitor of pyruvate dehydrogenase kinase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243120A1 (en) * 2019-05-31 2020-12-03 Imbria Pharmaceuticals, Inc. Methods of treating fibrosis using compounds that promote glucose oxidation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERLINER DOMINIK ET AL: "The Treatment of Heart Failure with Reduced Ejection Fraction", 22 May 2020 (2020-05-22), XP093206987, ISSN: 1866-0452, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643567/pdf/Dtsch_Arztebl_Int-117_0376.pdf> DOI: 10.3238/arztebl.2020.0376 *
KLONER ROBERT A. ET AL: "Stunned and Hibernating Myocardium: Where Are We Nearly 4 Decades Later?", vol. 9, no. 3, 4 February 2020 (2020-02-04), XP093207112, ISSN: 2047-9980, Retrieved from the Internet <URL:https://www.ahajournals.org/doi/pdf/10.1161/JAHA.119.015502> DOI: 10.1161/JAHA.119.015502 *
MARON MARTIN S ET AL: "Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 67, no. 12, 21 March 2016 (2016-03-21), pages 1399 - 1409, XP029469187, ISSN: 0735-1097, DOI: 10.1016/J.JACC.2016.01.023 *
See also references of WO2022125370A1 *

Also Published As

Publication number Publication date
EP4259138A1 (en) 2023-10-18
WO2022125370A8 (en) 2022-08-25
WO2022125370A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
EP3931564A4 (en) METHODS OF TREATMENT OF MAP3K8 POSITIVE TUMORS
EP3941921A4 (en) THERAPEUTIC METHODS OF TREATMENT OF HEPATITIS B
EP3958869A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF LUNG DISEASE RELATED TO BIOFILM
EP3990090A4 (en) RELEASE CATHETER AND METHODS OF TREATMENT OF DISEASE
EP4301410A4 (en) METHODS FOR TREATMENT OF THYROID EYE DISEASE
EP3565540A4 (en) METHODS FOR TREATMENT OF CARDIAC DISEASES
EP4229828A4 (en) METHODS OF TREATING FIBROSIS
EP4005586A4 (en) METHODS OF TREATMENT OF INTERFERON-BASED DISEASES
EP3893883A4 (en) METHODS OF TREATMENT OF DEPRESSION
EP4232039A4 (en) METHODS OF TREATING LUNG CANCER
EP3752161A4 (en) METHOD OF TREATMENT OF FIBROSE
EP4248212A4 (en) METHODS OF TREATING DISEASES AND DISORDERS
EP4346813A4 (en) METHODS FOR THE TREATMENT OF RETINAL VASCULAR DISEASES
EP3746067A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF PULMONARY EDEMA OR PUNGI
EP3829651A4 (en) METHOD OF IDENTIFYING PATIENTS LIKELY TO BENEFIT FROM TREATMENT WITH AN INHIBITOR TELOMERA
EP4419101A4 (en) METHODS FOR THE TREATMENT OF CNS DISEASES
EP3914589A4 (en) METHODS OF TREATMENT OF DISEASES WITH MAGL INHIBITORS
EP3821908A4 (en) METHODS OF PREVENTING OR TREATMENT OF PERIPHERAL NEUROPATHY OR PAIN RELATED TO A DISEASE WHERE PERIPHERAL NEUROPATHY OR ASTROCYTE DISEASE IS DETECTED
EP4395752A4 (en) Methods for treating CB1-, TRPA1-, and TRPV1-dependent diseases
EP4262814A4 (en) METHODS OF TREATING CASTOR-RELATED DISORDERS
EP4259138A4 (en) METHODS OF TREATING HEART DISEASE WITH MODIFIED FORMS OF TRIMETAZIDINE
EP3784231A4 (en) METHOD OF TREATMENT OF HIGH BLOOD PRESSURE
EP3720559A4 (en) METHOD OF TREATMENT OF PATIENTS WITH MYELODYLOPLASTIC SYNDROMS
EP4157278A4 (en) METHODS OF TREATING PULMONARY FIBROSIS
EP4125965A4 (en) METHOD FOR TREATING LUNG DISEASES WITH CELL-FREE AMBULANCE

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230606

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20231221

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20241008

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 295/088 20060101ALI20241001BHEP

Ipc: A61K 31/497 20060101ALI20241001BHEP

Ipc: C07D 213/80 20060101ALI20241001BHEP

Ipc: C07D 401/12 20060101ALI20241001BHEP

Ipc: C07D 241/04 20060101ALI20241001BHEP

Ipc: C07D 241/02 20060101ALI20241001BHEP

Ipc: A61P 9/00 20060101ALI20241001BHEP

Ipc: A61K 31/496 20060101ALI20241001BHEP

Ipc: A61K 31/495 20060101ALI20241001BHEP

Ipc: A61K 31/455 20060101AFI20241001BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250926